AI new pharmaceutical company Fermizi Technology completed a cumulative hundreds of millions of yuan A round of financing

AI new drug company Fermizi Technology announced the completion of a cumulative hundreds of millions of yuan A round of financing, investors include Panda Capital, Guangzhou Gold Control, Tongyu Capital and so on. Previously, the team had been led by Challenger Capital, Panda Capital and Pre-A round of financing.It is understood that this round of financing will be mainly used for team upgrades, the company's technical model and data model improvement, and related product pipeline cooperation number of expansion."Fermizi's projects in the last two years have been mostly PCC phases and before, and we hope to be able to cooperate in depth with pharmaceutical companies in the PCC stage, IND stage, and even clinical phase 1 in the future," said Deng Daiguo, founder and CEO of Fermizi Technology. At the same time, we will further increase our investment in algorithms and data to form a complete, new AI-based small molecule to develop solutions for the preclinical drug development process, while creating a richer product pipeline.Challenger Capital founding partner Tang Binsen said: "Challenger Capital through investment in companies like Fermizi using AI technology to drive new drug research and development to complement China's global new drug research and development of this backward status quo, the more China's backward industries have the opportunity, any future industry has the possibility of being replaced by AI technology, and think Fermizi team and other teams the biggest difference, is a strong sense of originality and mission." Liang Weihong,partner at panda capital, said: "We voted for Fermizi in Angel Wheel when we noticed the application of AI technology in the U.S. in the field of new drug research and development, and we believe that Chinese pharmaceutical companies need technological innovation more." But at the same time, there are great differences between china and the United States market, the requirements for the entrepreneurial team is higher, so in the end we chose to take the country as the team, value the team not only in the technical accumulation of precipitation, in the business model and path of thinking mature, in the to B market has a good execution. Lu, general manager of the Guangzhou Gold Control Fund, said: "We have always been bullish on the track of medical and health care, and China will be a golden age for the next two decades." The iteration of AI algorithm helps break through the efficiency bottleneck of domestic innovative drug research and development. Big water big fish, the world's outstanding AI biopharmaceutical company will be born in China. Dr. Deng has continuous entrepreneurial experience, a good understanding of the business model of TO B services, and the team has strong executive power. Fermizi's early involvement in the AI pharmaceutical field has a first-in-the-nation advantage, and a deep understanding of this field, we are optimistic about Fermizi. guo Luwei, managing partner ofTongyu Capital, said: "Tongyu Capital has long been bullish on artificial intelligence and medical health track, and the successful experience of the investment team in the past has made Tongyu Capital have a deep understanding of China's entrepreneurial environment and large health industry, corporate management, and we prefer 'super CEO'. Complementary capabilities, consistent concept team, Fermizi is the few we see in this track on the AI deep integration industry applications, and the team has a deep business understanding and practice of corporate services, the company's business progress and commercialization speed, as well as the recognition of higher customer reputation is the main reason for choosing Fermizi. According, Guangzhou Fermizi Technology Co., Ltd. was established in May 2015, the legal representative is Deng Daiguo. As a technology-driven new small molecule research and development technology enterprise, Fermizi will be biology, pharmaceutical chemistry, computer and other multidisciplinary deep integration, deep learning, intensive learning, generation of confrontation, big data, knowledge map and other artificial intelligence technology applied to new drug research and development, aimed at greatly improving the efficiency and success rate of new drug research and development, open up new boundaries of drug research and development, for diseases to provide more and better treatment programs.Through The FermiNet small molecule development platform based on deep learning, Fermizi can cover the entire process of targeting preclinical candidate compounds to PCC. From the selected target to the PCC stage, Fermizi can save 1-2 years compared to traditional pharmaceutical companies, greatly improving the efficiency of research and development;At present, in the direction of inflammation and metabolism, Fermizi has a number of product pipelines, have reached the PCC stage, and is expected to go to IND declaration in 2021. (
hunting cloud network
)